Sanford J. Madigan, Ph.D.

Senior Vice President, Business Development

Sanford J. Madigan brings over 18 years of industry experience to his role as senior vice president, business development at COI Pharmaceuticals. Dr. Madigan has been instrumental in developing companies’ infrastructure, establishing strategic direction, licensing founding and value-added technologies, negotiating strategic partnerships and corporate acquisitions.

He currently serves as president and chief executive officer of Sova Pharmaceuticals and Ankasa Regenerative Therapeutics, both Avalon Ventures portfolio companies. Dr. Madigan is the founding executive of Ankasa and raised $19 million in a syndicated Series A round.  Prior to his roles at COI, Sova and Ankasa, Dr. Madigan served as a co-founder and chief executive officer of Strategic Enzyme Applications (SEA), a San Diego-based clean technology company that was established, in part, as a strategic relationship with Monsanto. Prior to founding SEA, Dr. Madigan served in various venture-backed biotechnology companies; participating as a founder and/or senior manager in BioVerdant, Nereus Pharmaceuticals, Ambit, Xenopharm (acquired by Deltagen), X-Ceptor (acquired by Exelixis) and SIBIA Neurosciences (acquired by Merck).

Dr. Madigan performed his post-doctoral training at The Salk Institute for Biological Studies in La Jolla, California. He received his Ph.D. in genetics and his B.S. in biochemistry from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research.